Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM
Dejuan Kong(University of Michigan), Fazlul H. Sarkar(Wayne State University), Michael L. Cher(The Barbara Ann Karmanos Cancer Institute), Oudai Hassan(Henry Ford Health System), Dhananjay Chitale(Henry Ford Hospital), Clara Hwang(Henry Ford Health System), Yiwei Li(Ningxia Medical University), Wei Chen(Gansu University of Traditional Chinese Medicine), Nilesh Gupta(Henry Ford Health System), Shadan Ali(Wayne State University), Mani Menon(Henry Ford Hospital), Seema Sethi(Janssen (United States)), Isaac J. Powell(Wayne State University), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), Wael Sakr(Wayne State University), Lance K. Heilbrun(Wayne State University)
Cited by 215
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells
|PLoS ONE|2010|406
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
|PubMed|2002|383
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
|Clinical Cancer Research|2013|358